Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzman, Cristina B., Duvvuru, Suman, Akkari, Anthony, Bhatnagar, Pallav, Battioui, Chakib, Foster, Wendra, Zhang, Xiaotian Michelle, Shankar, Sudha S., Deeg, Mark A., Chalasani, Naga, Hardy, Thomas A., Kazda, Christof M., Pillai, Sreekumar G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944587/
https://www.ncbi.nlm.nih.gov/pubmed/29761171
http://dx.doi.org/10.1002/hep4.1171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944587/
https://www.ncbi.nlm.nih.gov/pubmed/29761171
http://dx.doi.org/10.1002/hep4.1171

Ejemplares similares